Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S. brand ...
A certain blood protein regarded as an early indicator of Alzheimer's disease also appears to play a role in other disorders. Researchers at DZNE and the Hertie Institute for Clinical Brain Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results